Based on the key indicators related to China SXT's liquidity, profitability, solvency, and operating efficiency, China SXT Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At present, China SXT's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 19.8 M, whereas Total Assets are forecasted to decline to about 21.9 M. Key indicators impacting China SXT's financial strength include:
The essential information of the day-to-day investment outlook for China SXT includes many different criteria found on its balance sheet. An individual investor should monitor China SXT's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in China SXT.
Please note, the presentation of China SXT's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, China SXT's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of China SXT's management manipulating its earnings.
China SXT Stock Summary
China SXT competes with Akanda Corp, Shuttle Pharmaceuticals, Painreform, Regencell Bioscience, and Procaps Group. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets in China. The company was founded in 2005 and is headquartered in Taizhou, China. China Sxt operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 88 people.
Specialization
Consumer Staples, Drug Manufacturers - Specialty & Generic
Comparative valuation techniques use various fundamental indicators to help in determining China SXT's current stock value. Our valuation model uses many indicators to compare China SXT value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across China SXT competition to find correlations between indicators driving China SXT's intrinsic value. More Info.
China SXT Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At present, China SXT's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China SXT's earnings, one of the primary drivers of an investment's value.
China SXT Pharmaceuticals Systematic Risk
China SXT's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. China SXT volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on China SXT Pharmaceuticals correlated with the market. If Beta is less than 0 China SXT generally moves in the opposite direction as compared to the market. If China SXT Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one China SXT Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of China SXT is generally in the same direction as the market. If Beta > 1 China SXT moves generally in the same direction as, but more than the movement of the benchmark.
About China SXT Financials
What exactly are China SXT Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include China SXT's income statement, its balance sheet, and the statement of cash flows. Potential China SXT investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although China SXT investors may use each financial statement separately, they are all related. The changes in China SXT's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on China SXT's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in China SXT Stock are looking for potential investment opportunities by analyzing not only static indicators but also various China SXT's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of China SXT growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0484
At present, China SXT's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
China SXT March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of China SXT help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of China SXT Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of China SXT Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing China Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build China SXT's daily price indicators and compare them against related drivers.
When running China SXT's price analysis, check to measure China SXT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China SXT is operating at the current time. Most of China SXT's value examination focuses on studying past and present price action to predict the probability of China SXT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China SXT's price. Additionally, you may evaluate how the addition of China SXT to your portfolios can decrease your overall portfolio volatility.